DEVONIAN ANNOUNCES THE CLOSING OF A $315,000 PRIVATE PLACEMENT AND AN ADDITIONAL LOAN OF $500,000
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE CLOSING OF A $315,000 PRIVATE PLACEMENT AND AN ADDITIONAL LOAN OF $500,000 QUEBEC, Québec – August 21, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD) is pleased to...
Dr George G. Zhanel joins Devonian’s Cannabinoids Scientific Advisory board
PRESS RELEASE For immediate release Dr George G. Zhanel joins Devonian’s Cannabinoids Scientific Advisory board. Quebec – July 23, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXv: GSD), a clinical stage biopharmaceutical corporation...
Devonian Announces the Filing of a New Patent Application related to use of Thylakoids as delivery system for Cannabinoïds and other Liposoluble Molecules
PRESS RELEASE For immediate release Devonian Announces the Filing of a New Patent Application related to use of Thylakoids as delivery system for Cannabinoïds and other Liposoluble Molecules. Quebec – June 5, 2019 – Devonian Health Group Inc. (“Devonian” or the...
Devonian signs a Binding Letter of Intent with Histapharm Inc. to extract and manufacture their proprietary botanical pharmaceutical product and to enter into a Strategic Partnership for the development of New Products
PRESS RELEASE For immediate release Devonian signs a Binding Letter of Intent with Histapharm Inc. to extract and manufacture their proprietary botanical pharmaceutical product and to enter into a Strategic Partnership for the development of New Products. ...
Devonian Health Group Announces the Formation of a Scientific Advisory Board with mandate to assist in the development of Cannabinoïds-based pharmaceutical products
PRESS RELEASE For immediate release Devonian Health Group Announces the Formation of a Scientific Advisory Board with mandate to assist in the development of Cannabinoïds-based pharmaceutical products. QUEBEC, April 10, 2019 – Devonian Health Group Inc....
Devonian Health Group announces the publication of results of in vitro assessment of the antioxidant and UV protection properties of thylakoid extracts in Journal of Cosmetic Dermatology
PRESS RELEASE For immediate release Devonian Health Group announces the publication of results of in vitro assessment of the antioxidant and UV protection properties of thylakoid extracts in Journal of Cosmetic Dermatology. QUEBEC, April 8, 2019 – Devonian...
Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019
PRESS RELEASE For immediate release Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019 Quebec, Quebec – April 2, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...
Devonian Health Group issues Securities In Interest Settlement Due To Debenture Holders and grants options
PRESS RELEASE For immediate release Devonian Health Group issues Securities In Interest Settlement Due To Debenture Holders and grants options NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. QUEBEC, March 29, 2019 – Devonian...
Devonian Announces voting results of the Annual General and Special Meeting
PRESS RELEASE For immediate release Devonian Announces voting results of the Annual General and Special Meeting QUÉBEC, Québec – January 31st, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical...
Devonian Health Group Provides an update on its Phase 2 Clinical Study in Atopic Dermatitis and Announces plans for the first photoprotection product issued from its Cosmeceutical R&D program
PRESS RELEASE For immediate release Devonian Health Group Provides an update on its Phase 2 Clinical Study in Atopic Dermatitis and Announces plans for the first photoprotection product issued from its Cosmeceutical R&D program QUEBEC, January 29, 2019 –...